Ariad Pharmaceuticals Inc., of Cambridge, Mass., reported net sales of leukemia drug Iclusig (ponatinib) of $8.3 million for the quarter ending Dec. 31 and sales of $45.2 million for the year. Read More
Ardelyx Inc., of Fremont, Calif., said it licensed to Paris-based Sanofi SA its phosphate transport NaP2b inhibitor program (also known as NaPi2b, Npt2b and SCL34A2) in exchange for an undisclosed up-front payment and total development and regulatory milestones potentially reaching up to $198 million. Read More
Hyperion Therapeutics Inc., of Brisbane, Calif., said results of a phase II study of glycerol phenylbutyrate (GPB) for the treatment of hepatic encephalopathy (HE) published in Hepatology showed that the trial met its primary endpoint, with significantly fewer patients treated with GPB experiencing HE events as compared to those receiving placebo. Read More
With phase III data from ulcerative colitis DNA-based drug Kappaproct (DIMS0150) due in the coming months, Index Pharmaceuticals AB has added $20 million to its balance sheet in advance. Read More
While the biopharma industry once again wants Canada placed on the U.S. Trade Representative’s priority watch list because of its policies that erode the value of drug patents, Eli Lilly and Co. has taken the matter into its own hands. Read More
Metreleptin, the biologic developed by Bristol-Myers Squibb Co.’s (BMS) wholly owned subsidiary Amylin Pharmaceuticals LLC, received an FDA green light on its PDUFA date of Feb. 24 as a replacement therapy to treat the complications of leptin deficiency, in addition to diet, in patients with ultra-rare congenital generalized or acquired generalized lipodystrophy (LD). Read More
Intermune Inc. plans to resubmit its new drug application (NDA) for Esbriet (pirfenidone) for idiopathic pulmonary fibrosis (IPF) in the third quarter of this year, based on home run phase III data from a trial called ASCEND that sent the company’s shares into the upper altitudes. Given a six-month review, Esbriet could hit the U.S. market as early as the second quarter of 2015. Read More
